This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community.
LOS ANGELES, CA - June 30, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company developing innovative treatments for suicidal depression and PTSD, is accelerating its push toward regulatory approval of NRX-100, a preservative-free intravenous ketamine formulation. The company has filed an application under the newly created FDA Commissioner's National Priority Voucher ("CNPV") program, which promises significantly shortened review timelines for drugs that meet urgent U.S. health priorities (https://ibn.fm/VeYud).
The new FDA voucher program aims to speed approval of drugs aligned with national health priorities.
NRX-100, a preservative-free ketamine, is also under an Abbreviated New Drug Application ("ANDA") with a priority review request.
NRx has submitted full CMC data and draft labeling for NRX-100, meeting key Commissioner's National Priority Voucher pre-qualification criteria.
The company's U.S.-based manufacturing aims to reduce foreign supply chain dependence and address diversion concerns.
A patent on the preservative-free process and a citizen petition to withdraw preserved ketamine could bolster NRx's market position.
The new CNPV program, announced by FDA Commissioner Marty Makary on June 17, is intended to bring promising treatments to market more quickly. Makary had previously identified psychedelic drugs for treatment of suicidal depression and PTSD as a national priority. For eligible drugs, the program
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to NRXP are available in the company's newsroom at https://ibn.fm/NRXP
Forward Looking Statements
Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.
About IBN
IBN is a cutting-edge communications and digital engagement platform providing tailored Platform Solutions for select private and public companies. Over the course of 19+ years, IBN has introduced over 70 investor facing brands to the investment public and amassed a collective audience of millions of social media followers. These distinctive investor brands amplify recognition and reach as well as help fulfill the unique needs of our rapidly growing and diverse base of client-partners. IBN will continue to expand our branded network of influential properties as well as leverage the energy and experience of our team of professionals to best serve our clients.
IBN's Platform Solutions provide access to: (1) our Dynamic Brand Portfolio (DBP) through 70+ investor facing brands; (2) article and editorial syndication to 5,000+ news outlets; (3) full-scale distribution to a growing Social Media Network (SMN) ; (4) a network of wire solutions via InvestorWire to effectively reach target markets and demographics; (5) Press Release Enhancement to ensure accuracy and impact; (6) a full array of corporate communications solutions; and (7) total news coverage solutions.
For more information, please visit www.IBN.fm
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer
Media Contact
IBN
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
View the original release on www.newmediawire.com